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Case Report
B.K., a 32-year-old Moroccan man, was admitted
to our department of internal medicine for abdominal
pain and vomiting. He reported loss of weight (15 kg
over 8 months) and migrant arthritis of the joints.
On admission his vital signs were normal, while
on examination a decreased vesicular murmur was
heard bilaterally in the lower part of the lungs. Dif-
fused tenderness of the abdomen, alopecia and facial
erythema were also found.
Blood exams showed a normocytic and nor-
mochromic anemia (hemoglobin 10.5 g/dL and mean
corpuscular volume 80 fL) and an increase of inflam-
matory indexes. An abdominal ultrasound revealed co-
pious free fluid. An x-ray of the abdomen showed
some air fluid levels. A computed tomography scan of
the thorax and of the abdomen confirmed ascites,
pleural effusion, inguinal, axillary and abdominal lym-
phadenitis, thickness of some portions of the intestine.
The patient was put on parenteral nutrition and an em-
piric antibiotic treatment was started.
He underwent an explorative laparoscopy that re-
vealed no abnormal findings (no free fluid or thickness
of the small intestine). The biopsy, done on some of the
mesenteric lymph nodes taken during the laparoscopy
procedure, revealed a slight inflammation of this tissue.  
The blood exams excluded a potential microbio-
logical etiology, such as HIV, QuantiFERON®-TB
(Cellestis Ltd., Carnegie, Victoria, Australia), Ep-
stein-Barr virus, cytomegalovirus, Brucella, Leish-
mania. On the other hand anti-nuclear antibodies
(ANA) (1:1280), extractable nuclear antibodies
(ENA), DNA, anti-Smith (Sm) antibodies were pos-
itive; the complement system was modified (C3: 50
mg/dL; C4 9 mg/dL) and a hypothyroidism with an
increased level of thyroglobulin antibodies was
found (3785 UI/mL).
A biopsy of the facial skin (affected by rush) was
also performed and led to a diagnosis of lupus ery-
thematosus.
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ABSTRACT
B.K. a Moroccan 32-year-old man was admitted to our hospital for abdominal pain and vomiting. He showed an increase of
inflammation indexes, abdominal free fluid, axillary, inguinal and abdominal lymphadenitis, pleural effusion, ascites and thickened
intestinal walls. The patient also presented alopecia and facial erythema, a positive anti-nuclear antibodies (ANA) test (1:1280).
Lastly the diagnosis of systemic lupus erythematosus (SLE) was made. The patient was treated with high doses of corticosteroid;
abdominal pain decreased and pleural effusion and ascites disappeared. After several days he started to complain of significant
chest pain. He had a troponin increased above 100 ng/mL, modified electrocardiogram, pericardial effusion and edema of ventricular
walls as in myocarditis. The patient was treated successfully with cyclophosphamide and pericardial effusion and chest pain dis-
appeared. After 1 month at the hospital the patient was discharged and referred to a rheumatologist for the follow up. Systemic
lupus erythematosus is an autoimmune disease in which autoantibodies and immune-complexes damage heart, joints, skin, blood
vessels, liver, kidneys and the nervous system. Ninety percent of individual diagnosed with SLE are women. The course is unpre-
dictable with periods of acute illness alternating with periods of remission. This is a typical disease that requires a differential di-
agnosis, because the symptoms may vary widely and are unpredictable. According to the American College of Rheumatology,
which drew up a reference list of 11 symptoms, SLE is confirmed when 4 out of the 11 symptoms are present simultaneously or
symptoms overlap on two separate occasions. Treatment can include corticosteroids and antimalarial drugs, intravenous im-
munoglobulins and cytotoxic drugs such as cyclophosphamide. Our case is exceptional because it is rare for a young man to be af-
fected. He had 5 out of 11 symptoms: malar rash, serositis, arthritis, hematologic disorder and ANA test positive.
Correspondence: Gozzi Cristina, Medicina Interna Area Critica,
AOU Policlinico di Modena, via del Pozzo 71, Modena, Italy.
Tel.: +39.059.4225491.
E-mail: gozzic@libero.it 
Key words: systemic lupus erythematosus, autoimmune
disease.
Received for publication: 12 September 2013.
Revision received: 23 December 2013.
Accepted for publication: 20 January 2014.
This work is licensed under a Creative Commons Attribution
NonCommercial 3.0 License (CC BY-NC 3.0).
©Copyright C. Gozzi et al., 2014
Licensee PAGEPress, Italy
Italian Journal of Medicine 2014; 8:189-192
doi:10.4081/itjm.2014.430
Italian Journal of Medicine 2014; volume 8:189-192
No
n-
co
me
r i
al 
us
e o
nly
Soon after the diagnosis, the patient was put on
methylprednisolone [500 mg/die intravenously (i.v.)
for three days and then 1 mg/kg] and intravenous im-
munoglobulins (IVIGs), achieving a gradual remis-
sion of abdominal pain. A couple of days later, the
patient complained of chest pain: there was an in-
crease of troponin (100 ng/mL) in his blood level and
the various electrocardiograms done in sequence
showed Q waves. 
The transthoracic echocardiogram showed a thick-
ness of the left ventricle with no obstruction of the
blood flow, hypokinesis of the septum and of the apex,
an ejection fraction of 45%, a small posterior pericar-
dial effusion with no constrictive effect.
The cardiac magnetic resonance imaging con-
firmed the diagnosis of pericarditis and myocarditis
with an irrelevant hypokinesis of the left ventricle (in
anterior and septal segments) and a much more re-
markable hypokinesis of the apex (anterior and infe-
rior segment); in these segments in T2 sequences a
higher intensity in tissue was noticed, as if to indicate
myocardial edema. The pericardial effusion with a
thickness of 1 cm was confirmed as well.
Therefore, in agreement with the rheumatologist,
the patient was also treated with cytotoxic drugs: ini-
tially we started with 200 mg of i.v. cyclophosphamide
every other day and then we switched to 100 mg orally.
Only then did we witness a gradual recovery of the
patient: he no longer had inflammation of the serous
membranes, on the echocardiogram follow up he had
a normal global kynesis, he no longer complained of
pain. He was then discharged and sent to the rheuma-
tologists for the follow up.
Discussion
Systemic lupus erythematosus (SLE) is a systemic
autoimmune disease (or autoimmune connective tis-
sue disease) that can affect any part of the body. As
can be seen in other autoimmune diseases, the immune
system attacks the body cells and tissues, triggering
inflammation and tissue damage. The disease occurs
9 times more often in women than in men. Statistics
show that the prevalence of SLE in the United States
ranges from 15 to 50 over 100,000 people. It manifests
itself in young adults in their 20s to 40s, even though
it can occur at any age.1
There is no one specific cause of SLE. There are,
however, environmental triggers and genetic suscep-
tibilities.
The onset can affect only one organ or be systemic
involving several parts of the body.
SLE is one of several diseases that in the Anglo-
Saxon countries are known as great imitators, be-
cause it often mimics or is mistaken for other
illnesses. SLE is a classical item in differential diag-
nosis, because SLE symptoms vary widely and come
and go unpredictably.
The disease varies from imperceptible and inter-
mittent signs and symptoms to a persistent condition
that can bring to death rapidly. The course of the dis-
ease is unpredictable, with periods of illness (called
flares) alternating with remissions. A complete recov-
ery occurs in less than 20% of the patients.2,3
Common initial and chronic complaints include
fever, joint pains, myalgia, fatigue, anorexia.
In general this disease involves more frequently
the musculoskeletal system, kidneys, blood, skin and
nervous system.4
The most common symptom is joint pain, in par-
ticular in the small joints of the hand (metacarpal-pha-
langeal joint 76%, proximal inter-phalangeal joint
82%) followed by wrists and knees. Muscle pain can
occur in 50% of the patients.5
Half of the patients present dermatological signs:
the classic malar rash (or butterfly rash) is an erythe-
matosus rash that involves cheeks, nose, ears and
chin. Some may have alopecia as well. Twenty per-
cent of patients have Raynaud’s phenomenon, which
is an excessive vasomotor response to cold or more
precisely a hyper-activation of the sympathetic nerv-
ous system causing extreme vasoconstriction of the
peripheral blood vessels with blood stasis that has a
spontaneous resolution.
The renal system can be injured in many ways and
develop a range of disorders from a slight proteinuria,
to painless hematuria, nephritic syndrome or renal fail-
ure. In most patients we can find a deposition of im-
mune complex along the glomerular basal membrane;
only about half of the patients develop glomeru-
lonephritis and persistent proteinuria.6 Patients with
diffused proliferative glomerulonephritis generally
need a more aggressive therapy with cytotoxic drugs,
because, if not treated rapidly and appropriately, they
can develop renal failure. In these patients a renal
biopsy can be helpful.
The nervous system can be damaged as well; in
general when the disease has already involved other
systems. We can have central nervous system disor-
ders and peripheral nervous system disorders. The
neurological symptoms include headaches, depres-
sion, seizures, cognitive dysfunction, mood and anxi-
ety disorders, polyneuropaties, psychosis.7-9
An SLE patient may have inflammation of various
parts of the heart, such as pericarditis (generally the
most common one), myocarditis, and endocarditis.
Endocarditis in SLE is typically non-infective due to
the sediment of immunocomplexes (Libman Sacks en-
docarditis), and involves either the mitral valve or the
tricuspid valve. Pleural effusion can also be seen.10,11
Gastrointestinal involvement manifests itself with
nausea, diarrhea, and abdominal pain. Vasculitis of the
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gastrointestinal tract is one of the most fearful com-
plications.
The blood tests generally reveal normocytic and
normochromic anemia, leukopenia and lymphopenia.
In 25% of the cases we can find high levels in the
venereal disease research laboratory test, due to the
presence of anti-phospholipid antibodies (aPL). If this
occurs, we generally define it as a false positivity for
venereal diseases (syphilis).
Other tests routinely performed in suspected SLE
patients aim to measure complement system levels,
since there may be low levels of C3 and C4. The level
of erythrocyte sedimentation rate is generally high. 
ANA and anti ENA are the most important sero-
logic tests for SLE. ANA screening may give positive
results in many connective tissue disorders and other
autoimmune diseases, and may occur in normal indi-
viduals as well. Subtypes of the ANA that are linked
to SLE and are positive in 70% of the patients are the
anti-double stranded DNA antibodies (dsDNA); sub-
types of ENA that are linked to SLE include anti-Sm
antibodies.
The prevalence of aPL ranges from 1% to 10% in
the general population, 16% in patients with rheuma-
toid arthritis and 30 to 40% in patients with SLE.
The strength of the correlation between aPL and
thrombosis varies among studies depending on type of
aPL test, study design and clinical population studied.
Although any vasculature can be affected by
thrombosis, stroke and transient ischemic attack are
the most common presentations of arterial thrombosis,
whereas deep vein thrombosis is the most common
presentation of venous thrombosis. 
The major cardiac manifestations of aPL include
valve disease, myocardial infarction, intracardiac
thrombosis. The commonest cardiac manifestation
of aPL is valve abnormalities in the form of vegeta-
tions and thickening similar to Libman-Sacks endo-
carditis in SLE. Left-sided valves are involved more
frequently; mitral valves are more commonly af-
fected than aortic valves. The predominant func-
tional abnormality is regurgitation, whereas stenosis
is rare. Valve abnormalities are usually asympto-
matic. Patients with valve abnormalities have a
higher incidence of arterial embolism than those
without valve disease. There is mounting evidence
that aPL is associated with an increased risk of my-
ocardial infarction.12
In 1982 the American College of Rheumatology
(ACR) drew up a reference list of 11 criteria, revised
in 1997, which is intended to be a classification tool
to simplify the diagnosis that quite often is very com-
plex. When 4 out of 11 criteria are present simultane-
ously or overlap on 2 separate occasions, the SLE
diagnosis is confirmed.
The symptoms are: i) malar rash (rash on cheeks);
ii) discoid rash (red, scaly patches on skin that cause
scarring); iii) serositis: pleuritis, pericarditis; iv) oral
ulcers (oral or nasopharyngeal ulcers); v) arthritis:
non-erosive arthritis of two or more peripheral joints,
with tenderness, swelling, or effusion; vi) photosen-
sitivity (exposure to ultraviolet light causes rash, or
other symptoms of SLE flare-ups); vii) hematologic
disorders: hemolytic anemia (low red blood cell
count) or leukopenia (white blood cell count
<4000/µL), lymphopenia (<1500/µL) or thrombocy-
topenia; viii) renal disorders: more than 0.5 g per day
of protein in urine or cellular casts seen in urine sam-
ples under a microscope; ix) positive ANA test; x)
immunologic disorders: positive anti-Sm, anti-
dsDNA, anti-phospholipid antibody, and/or false
positive serological test for syphilis; presence of anti-
single-stranded DNA in 70% of cases; xi) neurologic
disorder: seizures or psychosis.
The treatment of SLE involves preventing flares
and reducing their severity and duration when they
occur. Low levels of C3 and high levels of anti-
dsDNA antibodies are a negative prognostic factor and
require an aggressive treatment.
Due to the variety of symptoms and organ sys-
tems involved in this disease, an individualized as-
sessment of its severity is required to treat each
patient successfully. A mild form of SLE may be
treated with non-steroidal anti-inflammatory drugs
(NSAIDs), sometimes associated with hydroxy-
chloroquine which has been introduced in the treat-
ment of SLE since 1955 for cutaneous and articular
manifestations. Immunosuppressants, as methotrex-
ate and cyclosporine, can be used as well: the former
for a better control of joint involvement, and the lat-
ter for hematologic abnormalities. Severe cases with
severe organ and hematologic complications can be
treated with i.v. NSAIDs and cyclophosphamide,
which are used in particular for severe glomeru-
lonephritis. IVIGs may be helpful to control SLE
with organ involvement, or vasculitis.13,14
A new treatment specifically targeted against
SLE is belimumab. It is an IgG1 monoclonal anti-
body that inhibits the activity of the soluble cytokine
B-lymphocyte stimulator, also known as B-cell acti-
vating factor. It is targeted to the fundamental pathol-
ogy of SLE and has been widely regarded as a step
change in treatment options. It was recently licensed
in the USA and in Europe for the treatment of au-
toantibody-positive SLE. The European indication is
for severely affected SLE patients with active, au-
toantibody-positive disease and a high degree of dis-
ease activity exemplified by positive anti-dsDNA
and low complement despite standard therapy. Beli-
mumab is administered by intravenous infusion rec-
ommended at 10 mg/kg on days 0, 14 and 28 and
subsequently at 28-day intervals.15
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Conclusions
The peculiarity of this case of SLE is that the pa-
tient was a young man and that the onset was abdom-
inal pain with bowel obstruction. The laparoscopic
procedure was not useful for the diagnosis of SLE, but
was helpful in ruling out other causes of abdominal
peritonitis. As the Anglo-Saxons say, SLE is the great
imitator. Ascites, abdominal lymphadenitis and the
thickness of some portions of the bowels had to be
considered in the differential diagnosis with inflam-
matory bowel disease (Crohn’s disease), systemic in-
flammation that can cause sieritis, like tuberculosis or
peritoneal carcinosis. Moreover, when the patient
started to have heart problems, a differential diagnosis
was mandatory to understand if he had pericarditis,
myocarditis or acute myocardial ischemia. Also, based
on the SLE disease criteria, many of the patient’s or-
gans were damaged. In fact, he had 5 of the criteria
listed by ACR (malar rash, serositis, non-erosive
arthritis, hematologic disorder, positive anti-Sm, anti-
dsDNA).
SLE is a great challenge for physicians, because
this disease can involve many organs and systems.
Only a thorough knowledge and a correct differential
diagnosis can lead to the right diagnosis and an ade-
quate medical therapy and patient management.
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